Sarepta Therapeutics, Inc.
Cambridge, MA
- UEI
- YKM9HZ3EH6X1
- CAGE
- 49WU1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
FVMHHCGQKM83
-
Parent
FVMHHCGQKM83
- SAM.gov registration date
- Physical address
- 215 First St, Cambridge, MA 02142, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| IM formulation feasiblity study | ACC Aberdeen Proving Ground | $3,786,506 | |
| Antibacterial and anti-shiga | Bureau of Medicine and Surgery (Navy) | $100,000 | |
| The transformational medical | Bureau of Medicine and Surgery (Navy) | $99,000 | |
| Advanced development of hemorrhagic | ACC Aberdeen Proving Ground | $106,393,196 | |
| H1N1 countermeasure development | Defense Threat Reduction Agency | $12,324,641 |
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Quick answers
Is Sarepta Therapeutics, Inc. registered in SAM.gov?
Yes. Sarepta Therapeutics, Inc.'s SAM.gov registration is active through May 4, 2027.
What is Sarepta Therapeutics, Inc.'s most recent federal award?
Sarepta Therapeutics, Inc.'s most recent federal contract award is IM formulation feasiblity study (W911QY12C0117), from ACC Aberdeen Proving Ground, on August 23, 2012.
On GovTribe
See Sarepta Therapeutics, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors